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Dientamoeba fragilis is a debated protozoan parasite that is often detected in stools of patients with
chronic gastro-intestinal complaints. A retrospective follow-up study of a large cohort of patients was
performed to better understand the natural course of the infection and possible treatment options. D. fra-
giliswas spontaneously cleared in 41% of untreated cases. With an eradication rate of 98%, treatment with
paromomycin appeared more effective than treatment with clioquinol (83%) or metronidazole (57%).
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Dientamoeba (D.) fragilis is one of the most common protozoan
organisms detected in human stools, with reported frequencies up
to 30% (Johnson et al., 2004; Stensvold et al., 2007; Schuster and
Jackson, 2009; Barratt et al., 2011). D. fragilis was originally de-
scribed as an a-pathogenic protozoan organism, but over the years
many reports have provided indications for the pathogenic poten-
tial of D. fragilis (Johnson et al., 2004; Barratt et al., 2011). Abdom-
inal pain and diarrhea are commonly reported in patients infected
with D. fragilis in the absence of other bowel pathogens (Barratt
et al., 2011). Furthermore, eradication of D. fragilis by treatment
is frequently associated with clinical improvement of symptoms
(Girginkardesler et al., 2003; Bosman et al., 2004; Johnson et al.,
2004; Vandenberg et al., 2007). For these reasons, persisting
D. fragilis infestations are often treated with the intention to erad-
icate this protozoon from the gut.
Although D. fragilis infections are frequently detected and trea-
ted, there is no consensus as to the best treatment for dientamoebi-
asis (Johnson et al., 2004; Barratt et al., 2011). Until now only 11
studies on the efﬁcacy of drugs to eradicate D. fragilis have been
published (see Table 1 for an overview). These 11 studies investi-
gated the efﬁcacy of 12 distinct drugs, of which eight drugs werePublished by Elsevier Ltd.
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Open acinvestigated by a single study only. So far, only a single randomized
study has been performed inwhich the treatment efﬁcacy ofmetro-
nidazole was compared to that of ornidazole (Kurt et al., 2008) and
all other studies had a retrospective study design. These studies re-
ported eradication efﬁcacies that were either low (50% for erythro-
mycin (Preiss et al., 1991), 75% for doxycycline (Preiss et al., 1991),
and 67–89% for metronidazole (Vandenberg et al., 2006; Stark et al.,
2010), or the result of very small retrospective cohort studies
involving maximal 27, 12, 9 and 15 patients for clioquinol (81–
100% (Bosman et al., 2004; Stark et al., 2010)), iodoquinol (83–
100% (Spencer et al., 1982; Millet et al., 1983), diphetarsone (100%
(Keystone et al., 1983)) and paromomycin (80–100% (Vandenberg
et al., 2007; Stark et al., 2010)), respectively. Two compounds, sec-
nidazol and ornidazol, were reported by single studies to have a
high eradication efﬁcacy for D. fragilis (93% and 97%, respectively)
in 56 and 34 patients (Girginkardesler et al., 2003; Kurt et al.,
2008). Finally, it is unclear to what extent D. fragilis infections are
spontaneously cleared, which may further hamper the interpreta-
tion of data regarding the eradication rates associated with some
drugs. Therefore, the current information on the efﬁcacy of drugs
for eradication of D. fragilis is surprisingly small and hampers the
formulation of unambiguous guidelines for treatment of dient-
amoebiasis, which is for instance demonstrated by the listing of four
recommended drugs for treatment of dientamoebiasis in the latest
Medical Letter (2010).
In order to better understand the natural course of the disease
and the efﬁcacy of potential treatment options, we analyzed the re-
sults of a retrospective follow-up study of a relatively large cohort
of 93 patients with a documented D. fragilis infection.cess under CC BY-NC-ND license.
Table 1
Reported parasitological cure rate for Dientamoeba fragilis.
Drug Efﬁcacy
(%)
Patients included
(n)
Ref.
Clioquinol 100 3 Bosman et al. (2004)
81 27 Stark et al. (2010)
Diphetarsone 100 9 Keystone et al. (1983)
Doxycycline 75 4 Preiss et al. (1991)
Erythromycin 50 6 Preiss et al. (1991)
Hydroxychinoline 20 5 Preiss et al. (1991)
Iodoquinol 83 12 Millet et al. (1983)
100 3 Spencer et al. (1982)
Metronidazole 84 41 Banik et al. (2011)
89 28 Stark et al. (2010)
70 56 Kurt et al. (2008)
67 12 Vandenberg et al.
(2006)
69 10 Bosman et al. (2004)
70 91 Preiss et al. (1991)
Ornidazole 93 56 Kurt et al. (2008)
Oxytetracycline 90 9 Preiss et al. (1991)
Paromomycin 100 5 Stark et al. (2010)
80 15 Vandenberg et al.
(2007)
100 4 Vandenberg et al.
(2006)
Secnidazole 97 34 Girginkardesler et al.
(2003)
Table 2
Characteristics of patients at presentation with a Dientamoeba fragilis infestation.
Demographic data n %
Patients 93
Age (median, IQR) 41 (29, 49)
Male gender 27 29
Female gender 66 71
Visit to the (sub) tropics (n = 78)a 72 92
Clinical symptoms n %
Duration of complaints (n = 70)a
0–1 month 7 10
1–3 months 6 9
3–6 months 11 16
More than 6 months 46 66
Type of complaints (n = 83)a Present (n) Present (%)
Abdominal pain 31 37
Diarrhea 35 42
Malaise 42 51
Weight loss 17 20
Laboratory ﬁndings Median (IQR) N
Blood leukocyte count, 109/L 6.5 (5.7, 7.5) 77
Blood eosinophil count, 109/L 0.1 (0.1, 0.2) 42
C-reactive protein, mg/L 2 (1, 5) 75
Erythrocyte sedimentation rate, mm/h 7 (3, 11) 72
Stool examination n %
Blastocystis hominis 69 74
Endolimax nana 8 9
Entamoeba coli 8 9
Entamoeba hartmanni 1 1
Iodamoeba butschlii 2 2
a Speciﬁed data on travel history, duration of complaints and type of complaints
was available in the medical records for 78, 70 and 83 patients, respectively.
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This retrospective cohort study was performed at the Institute
for Tropical Diseases of the Harbor Hospital in Rotterdam, TheNeth-
erlands, which is a national referral center for adult patientswho re-
cently visited tropical countries. Patients were included when
D. fragiliswas demonstrated in a stool sample analyzed in the period
2004–2010 by Triple Feces Test (TFT), an all-round and sensitive
method for microscopic detection of ‘helminth ova and protozoa,
among which trophozoites of D. fragilis (van Gool et al., 2003). In
addition, a follow-up stool sample had to be available for evaluation
of an empirical treatment or for evaluation of the natural course of
the infestation in case of untreated patients. The majority of the in-
cluded patients had gastro-intestinal symptoms and all were diag-
nosed with D. fragilis after exclusion of viral, bacterial and
parasitological causes of gastro-intestinal illness by thorough inves-
tigations including fecal cultures for pathogenic bacteria (Salmo-
nella, Shigella and Campylobacter) and PCR analysis for Rotavirus,
Norovirus and Adenoviruses. In the majority of the patients the
investigations also included upper and lower GI endoscopy, histo-
logical examination of duodenal and colonic biopsy specimens,
anti-trans Tissue Glutamate antibodies determination as well as
hydrogen breath tests for exclusion of lactose intolerance. Empirical
treatment with either paromomycin (3 daily doses of 500 mg for
7–10 days), clioquinol (3 daily doses of 250 mg for 7 days) ormetro-
nidazole (3 daily doses of 500 mg for 7–10 days) was prescribed
off-label on doctor’s declaration and after informed consent of the
patient. The patient records of all included patients were retrospec-
tively examined for demographic data, therapy and clinical follow-
up data. Patientswith an age of less than 18 years and those patients
who were treated for another protozoal or helminth infection
were excluded. The time interval between two TFT analyses was
truncated at 180 days. Parasitological eradication was deﬁned
as complete clearance of parasites in the subsequent stool
examination.3. Results and discussion
In the study period 5491 outpatients were examined for gastro-
intestinal parasites by TFT andD. fragiliswas demonstrated in stools
of 451 patients (8%) ofwhich 93 patients fulﬁlled the inclusion crite-
ria. General demographic and clinical characteristics of the included
patients with D. fragilis at presentation are shown in Table 2.
Diarrhea (42%), abdominal pain (37%) and malaise (51%) were
frequently observed. The laboratory parameters C-reactive protein,
leukocyte and eosinophil counts were not elevated (Table 2). Pa-
tientswithD. fragilis frequently had co-infestationswith Blastocystis
sp. (74%) and a-pathogenic protozoa (<10% for individual species)
(Table 2).
The 93 included patients received a total of 102 treatments.
Three patients received two treatments (ﬁrst no treatment fol-
lowed by paromomycin treatment) and another three patients re-
ceived three subsequent treatments (one received no treatment
ﬁrst, then metronidazole treatment and ﬁnally paromomycin
treatment, another received paromomycin treatment ﬁrst, fol-
lowed by two treatments with metronidazole, and the third patient
received paromomycin treatment ﬁrst, then no treatment and then
paromomycin treatment combined with doxycycline). Therefore,
results could be examined of 102 treatments with either paromo-
mycin (n = 61), clioquinol (n = 12), metronidazole (n = 7) or no
treatment (n = 22). This ‘wait and see’ policy was considered to
represent the natural course of D. fragilis infestation. In 30 treat-
ment cases (paromomycin n = 27, clioquinol n = 2, metronidazole
n = 1) treatment was combined with doxycycline. Mean time be-
tween analysis of subsequent stool samples was 62–76 days and
did not differ signiﬁcantly between treatment regimens. Because
treatment was not started directly after laboratory diagnosis of
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visit, the second stool sample was collected shortly after comple-
tion of treatment, which minimizes reinfection as a cause of per-
sisting D. fragilis infections.
D. fragilis was spontaneously cleared in 41% of the untreated
cases. Treatment with paromomycin, clioquinol and metronidazole
was associated with eradication rates of 98%, 83% and 57%, respec-
tively (Fig. 1). Although patient numbers in each treatment group
are uneven, statistical analysis showed that paromomycin treat-
ment had superior eradication rates compared to both metronida-
zole and no treatment (P < 0.005) and a trend towards superiority
over clioquinol (P = 0.06) (Fig. 1). Treatment with clioquinol was
signiﬁcantly more effective when compared to ‘‘wait and see’’
(P < 0.05). Metronidazole treatment was not signiﬁcantly more
effective than a ‘wait and see’ policy (P = 0.667). Statistical analysis
showed that the eradication rates of paromomycin, clioquinol or
metronidazole were not affected by a Blastocystis sp. co-infestation
or a combined treatment including doxycycline. Furthermore, the
time interval between the ﬁrst and subsequent follow-up stool
examination did not signiﬁcantly differ between the patient
groups.
The retrospective design of this study may hamper the general-
izability of the ﬁndings of this study, because (1) the various treat-
ment modes were not assigned randomly, (2) an all-round
microscopic detection method was used instead of a more sensi-
tive D. fragilis PCR method (Bruijnesteijn van Coppenraet et al.,
2009), and (3) a placebo-control was lacking. Since in this study
gastro-intestinal complaints were not systematically recorded
nor evaluated, this study focused on eradication of D. fragilis as a
hard end-point in relation to various treatment modes but not on
resolution of gastro-intestinal complaints or evaluation of the
pathogenic potential of D. fragilis. However, even within this
framework of limitations, the following clinical relevant observa-
tions could be made. First, the natural course of D. fragilis infesta-
tion in untreated patients is characterized by a spontaneous
clearance in 41% of cases. Second, this study suggests the superior
efﬁcacy of paromomycin for eradication of D. fragilis in adults (98%)
as compared to treatment with metronidazole and possibly also to
clioquinol. In this study the eradication efﬁcacy of metronidazole
was low (57%), but the relatively small number of included
patients treated with metronidazole (n = 7) prohibits ﬁrm*
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Fig. 1. Eradication efﬁcacy of treatment for Dientamoeba fragilis. Parasitological
cure efﬁcacy was deﬁned as clearance of parasites in the subsequent stool
examination. Numbers in the bars represent number of included treatments. Pair
wise statistical signiﬁcant differences are indicated, with ⁄ and ⁄⁄ representing P-
values of <0.03 and <0.003, respectively.conclusions on the eradication efﬁcacy of this drug. Although the
eradication efﬁcacies might be lower when a more sensitive PCR
method had been used, the observed relative differences in drug
efﬁcacy are not dependent on the sensitivity of the detection
method.
The high efﬁcacy of paromomycin was suggested by previous
reports for small numbers of patients (maximal 15) comprising
predominantly children (Vandenberg et al., 2006, 2007; Stark
et al., 2010). This study now showed that paromomycin is a highly
effective drug for treatment of D. fragilis in a large group of adult
patients, since 60/61 (98%) patients cleared D. fragilis after paromo-
mycin treatment. Our observations seem to justify validation of the
treatment efﬁcacy of paromomycin for eradication of D. fragilis in
properly designed placebo-controlled trials in adults and may be
of help in evaluating the pathogenic potential of D. fragilis in the
etiology of persistent gastro-intestinal complaints.
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